Neonmind’s NEO-002 artificial psilocybin candidate will be studied as a minimal-dose procedure to control and suppress individual urge for food. The corporation has secured pharmaceutical quality synthetic psilocybin from Psygen and anticipates initiating a Period I/II proof-of-thought review for NEO-001 in the near long term. Lower doses of about https://elizabethg556idy0.wikiitemization.com/user